Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy

Francesco Perri, Franco Ionna, Francesco Longo, Giuseppina Della Vittoria Scarpati, Carmine De Angelis, Alessandro Ottaiano, Gerardo Botti, Francesco Caponigro

Research output: Contribution to journalReview article

Abstract

Head and neck carcinoma (HNC) are diseases arising from several tracts of the aerodigestive ways. Most HNC are squamous cell carcinoma (SCCHN). Immunotherapy is a treatment strategy aimed to reinforce the immune system. Several types of immunotherapy are available in the clinical scenario. Checkpoint inhibitors were developed later in SCCHN; nivolumab and pembrolizumab have reached the clinical approval, having both drugs demonstrated to significantly improve the overall survival, if compared with the standard of treatment (according to the results of the CheckMate 141 and KEYNOTE-040 trials). Nevertheless, immunotherapy may fail because of the genetics of SCCHN. In fact, two genetically different types of SCCHN have been discovered, one virus-related (HPV) and the other mutagens-related. They seem to show in clinical trials very different responses to immunotherapy. Given the existence of a number of factors predictive of response to immunotherapy in SCCHN, a future clinical approach may be to characterize the genetic and immunologic feature of SCCHN and to perform a well-tailored immunotherapy. This review will summarize the main immunotherapy strategies available in SCCHN, discussing their real efficacy, highlighting also the ways to improve them.

Original languageEnglish
Pages (from-to)262-274
Number of pages13
JournalTranslational Oncology
Volume13
Issue number2
DOIs
Publication statusPublished - Feb 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Immune Response Against Head and Neck Cancer : Biological Mechanisms and Implication on Therapy. / Perri, Francesco; Ionna, Franco; Longo, Francesco; Della Vittoria Scarpati, Giuseppina; De Angelis, Carmine; Ottaiano, Alessandro; Botti, Gerardo; Caponigro, Francesco.

In: Translational Oncology, Vol. 13, No. 2, 02.2020, p. 262-274.

Research output: Contribution to journalReview article

@article{8e40a2c5fb184a29b8eb26542daf6be3,
title = "Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy",
abstract = "Head and neck carcinoma (HNC) are diseases arising from several tracts of the aerodigestive ways. Most HNC are squamous cell carcinoma (SCCHN). Immunotherapy is a treatment strategy aimed to reinforce the immune system. Several types of immunotherapy are available in the clinical scenario. Checkpoint inhibitors were developed later in SCCHN; nivolumab and pembrolizumab have reached the clinical approval, having both drugs demonstrated to significantly improve the overall survival, if compared with the standard of treatment (according to the results of the CheckMate 141 and KEYNOTE-040 trials). Nevertheless, immunotherapy may fail because of the genetics of SCCHN. In fact, two genetically different types of SCCHN have been discovered, one virus-related (HPV) and the other mutagens-related. They seem to show in clinical trials very different responses to immunotherapy. Given the existence of a number of factors predictive of response to immunotherapy in SCCHN, a future clinical approach may be to characterize the genetic and immunologic feature of SCCHN and to perform a well-tailored immunotherapy. This review will summarize the main immunotherapy strategies available in SCCHN, discussing their real efficacy, highlighting also the ways to improve them.",
author = "Francesco Perri and Franco Ionna and Francesco Longo and {Della Vittoria Scarpati}, Giuseppina and {De Angelis}, Carmine and Alessandro Ottaiano and Gerardo Botti and Francesco Caponigro",
year = "2020",
month = "2",
doi = "10.1016/j.tranon.2019.11.008",
language = "English",
volume = "13",
pages = "262--274",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "2",

}

TY - JOUR

T1 - Immune Response Against Head and Neck Cancer

T2 - Biological Mechanisms and Implication on Therapy

AU - Perri, Francesco

AU - Ionna, Franco

AU - Longo, Francesco

AU - Della Vittoria Scarpati, Giuseppina

AU - De Angelis, Carmine

AU - Ottaiano, Alessandro

AU - Botti, Gerardo

AU - Caponigro, Francesco

PY - 2020/2

Y1 - 2020/2

N2 - Head and neck carcinoma (HNC) are diseases arising from several tracts of the aerodigestive ways. Most HNC are squamous cell carcinoma (SCCHN). Immunotherapy is a treatment strategy aimed to reinforce the immune system. Several types of immunotherapy are available in the clinical scenario. Checkpoint inhibitors were developed later in SCCHN; nivolumab and pembrolizumab have reached the clinical approval, having both drugs demonstrated to significantly improve the overall survival, if compared with the standard of treatment (according to the results of the CheckMate 141 and KEYNOTE-040 trials). Nevertheless, immunotherapy may fail because of the genetics of SCCHN. In fact, two genetically different types of SCCHN have been discovered, one virus-related (HPV) and the other mutagens-related. They seem to show in clinical trials very different responses to immunotherapy. Given the existence of a number of factors predictive of response to immunotherapy in SCCHN, a future clinical approach may be to characterize the genetic and immunologic feature of SCCHN and to perform a well-tailored immunotherapy. This review will summarize the main immunotherapy strategies available in SCCHN, discussing their real efficacy, highlighting also the ways to improve them.

AB - Head and neck carcinoma (HNC) are diseases arising from several tracts of the aerodigestive ways. Most HNC are squamous cell carcinoma (SCCHN). Immunotherapy is a treatment strategy aimed to reinforce the immune system. Several types of immunotherapy are available in the clinical scenario. Checkpoint inhibitors were developed later in SCCHN; nivolumab and pembrolizumab have reached the clinical approval, having both drugs demonstrated to significantly improve the overall survival, if compared with the standard of treatment (according to the results of the CheckMate 141 and KEYNOTE-040 trials). Nevertheless, immunotherapy may fail because of the genetics of SCCHN. In fact, two genetically different types of SCCHN have been discovered, one virus-related (HPV) and the other mutagens-related. They seem to show in clinical trials very different responses to immunotherapy. Given the existence of a number of factors predictive of response to immunotherapy in SCCHN, a future clinical approach may be to characterize the genetic and immunologic feature of SCCHN and to perform a well-tailored immunotherapy. This review will summarize the main immunotherapy strategies available in SCCHN, discussing their real efficacy, highlighting also the ways to improve them.

UR - http://www.scopus.com/inward/record.url?scp=85076841168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076841168&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2019.11.008

DO - 10.1016/j.tranon.2019.11.008

M3 - Review article

AN - SCOPUS:85076841168

VL - 13

SP - 262

EP - 274

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 2

ER -